Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Research and development spending
3Y CAGR
+44.8%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
3x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $51.28M | +34.4% |
| 2024 | $38.16M | +38.3% |
| 2023 | $27.60M | +63.4% |
| 2022 | $16.89M | -24.4% |
| 2021 | $22.36M | - |